Botulism is caused by a bacterium called Clostridium botulinum (C. botulinum). This bacteria releases a neurotoxin, which is a poison that attacks your nervous system. Among the numerous types of foodborne illnesses, this botulism is one of the most dangerous. These bacteria toxins are some of the powerful toxins known to science. They act on the nervous system (including the nerves, brain, and spinal cord) and cause paralysis (muscle weakness), even leading to life-threatening situations. Types of botulism include infant botulism, wound botulism, and food-borne botulism.
According to the CDC, in 2016, a total of 205 confirmed botulism cases were reported in the United States. Among them, 150 (73%) cases were of infant botulism, 29 (14%) cases were of food-borne botulism, 24 (12%) cases were of wound botulism, and 3 (1%) cases were of unknown etiology.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence